---

Emergency Psychiatric Presentations: Complete Guide

---

Overview of the Emergency Psychiatric Assessment

1. Safety first - ensure safety of patient, staff, and environment; remove dangerous objects
2. Medical clearance - rule out organic causes (glucose, electrolytes, toxicology screen, thyroid, head CT if indicated)
3. Rapid mental status exam - level of consciousness, orientation, behavior, speech, affect, thought content
4. History - from patient, family, EMS, collateral sources; medication history is critical
5. Risk stratification - suicidality, homicidality, capacity, need for hospitalization vs. outpatient

---

1. ACUTE AGITATION / EXCITED STATE

Presentation

• Motor restlessness, pacing, threatening behavior, shouting, inability to sit still
• May result from psychotic symptoms (frightening delusions, command hallucinations), mania, delirium, substance intoxication/withdrawal, akathisia, or personality disorders

Approach - Differentiate the cause first

• Akathisia vs. psychotic agitation: if patient is on a first-generation antipsychotic (FGA), trial anticholinergic (benztropine) or propranolol to distinguish
• Delirium: waxing/waning consciousness, disorientation - always organic until proven otherwise
• Substance intoxication: stimulants (sympathomimetic signs), alcohol/benzodiazepines (sedation, ataxia), PCP (dissociation, nystagmus)

Management

• Calm, low-stimulation environment; de-escalation techniques; remove triggers
• Verbal engagement: speak slowly, non-threatening posture, offer choices
• Avoid physical restraint if possible; if used, must monitor closely (risk of positional asphyxia)

• Agitation from alcohol/benzodiazepine withdrawal
• Stimulant (cocaine, methamphetamine) intoxication
• When cause is unclear and organic etiology is possible

• Lorazepam: respiratory depression - avoid in severe respiratory compromise; caution in hepatic failure (lorazepam is safer than diazepam in liver disease due to direct glucuronidation)
• Haloperidol: QTc > 500 ms (risk of torsades); Parkinson's disease / Lewy Body Dementia (severe EPS/NMS risk); known allergy
• IM Olanzapine: must NOT be combined with IM/IV benzodiazepines within 2 hours - risk of fatal respiratory depression; caution in QTc prolongation
• Ziprasidone: significant QTc prolongation; avoid in known cardiac arrhythmia or concomitant QT-prolonging drugs
• Dexmedetomidine: bradycardia, hypotension - avoid in hemodynamic instability

---

2. SUICIDAL PATIENT

Presentation

• Active suicidal ideation with/without plan, recent attempt, presenting after self-harm

Risk Assessment - Columbia Suicide Severity Rating Scale (C-SSRS) + Clinical Judgment

• Previous suicide attempt (single strongest predictor)
• Specific, lethal plan with access to means (firearms, medications stockpiled)
• Severe hopelessness (Beck Hopelessness Scale)
• Major depressive disorder, bipolar disorder, schizophrenia, borderline personality disorder
• Active alcohol/substance use
• Social isolation, recent major loss (bereavement, financial, relationship)
• Male sex, age >45 or adolescent
• Recent discharge from psychiatric hospital
• Command hallucinations to harm self
• Impulsivity, agitation, severe anxiety, insomnia

Management

1. Immediate safety: 1:1 observation; remove all ligature risks, sharp objects, medications from environment
2. Medical assessment: treat any co-ingestion or physical injury
3. Psychiatric assessment: direct, empathetic interview; involve family (with consent)
4. Safety planning: collaboratively create a crisis safety plan (warning signs, coping strategies, crisis contacts)
5. Disposition decision:
   • Involuntary hospitalization: imminent risk, no capacity, refuses voluntary admission
   • Voluntary hospitalization: high-risk but cooperative; poor outpatient support
   • Intensive outpatient: low-to-moderate risk; robust support; means restriction confirmed; follow-up within 24-48 hrs
6. Pharmacotherapy: acute presentation - benzodiazepines for severe anxiety/agitation; start or continue mood stabilizer/antidepressant per underlying diagnosis
   • Lithium: evidence for anti-suicidal effect in bipolar disorder - reduces risk by ~60-80%
   • Clozapine: only FDA-approved agent for reducing suicidality in schizophrenia/schizoaffective disorder

---

3. ACUTE PSYCHOSIS

Presentation

• Delusions, hallucinations, disorganized thought/speech/behavior, negative symptoms, first episode vs. relapse

Approach

• Rule out organic psychosis: delirium, CNS infection, toxic ingestion, thyroid storm, Wernicke encephalopathy, autoimmune encephalitis (anti-NMDA receptor), metabolic
• First-episode psychosis: full workup mandatory (MRI brain, LP if febrile, anti-NMDA Ab, toxicology)

Management

• Second-generation antipsychotics (SGAs) preferred for first episode (less EPS)
• Target D2 receptor occupancy: 60-70% for FGAs/typical SGAs; >90% for partial agonists (aripiprazole); ~40% for clozapine and quetiapine

• All antipsychotics: Avoid in Lewy Body Dementia (severe sensitivity; up to 57% risk of severe adverse reactions, including irreversible parkinsonism)
• Clozapine: history of clozapine-induced agranulocytosis; bone marrow depression; severe CNS depression; uncontrolled epilepsy; absolute neutrophil count < 1500
• High-potency FGAs (haloperidol, fluphenazine): Parkinson's disease; history of NMS; QTc > 500 ms

---

4. NEUROLEPTIC MALIGNANT SYNDROME (NMS)

Presentation - Classic Tetrad

1. Altered mental status (confusion, stupor, coma) - usually first to appear
2. Muscle rigidity - "lead pipe" and "cogwheel"; most prominent feature, responsible for most complications
3. Hyperthermia - can lag >24 hours after other symptoms; may exceed 40°C
4. Autonomic instability - tachycardia, diaphoresis, labile BP, tachypnea, sialorrhea

Diagnostic Criteria (Tintinalli Table)

• Fever > 38°C
• Muscular rigidity
• Altered mental status
• Autonomic instability
• Elevated CK
• Dopamine antagonist exposure / dopamine agonist withdrawal
• Exclusion of other causes

Management

1. Stop all antipsychotics and potentiating drugs (anticholinergics, antihistamines, lithium) immediately
2. IV fluid resuscitation - maintain urine output >1 mL/kg/hr to prevent acute renal failure from myoglobinuria
3. External cooling - ice packs, cooling blankets; acetaminophen/NSAIDs NOT effective (temperature is from muscle rigidity, not hypothalamic reset)
4. Benzodiazepines (lorazepam 1-2 mg IV every 2-4 hours) - reduce agitation, sympathetic activity, muscle contraction
5. Airway management - early intubation if: hypersalivation, dysphagia, acidosis, hypoxia, fever with rigidity; use non-depolarizing agents (rocuronium) - NOT succinylcholine (risk of fatal hyperkalemia from rhabdomyolysis)
6. Specific pharmacotherapy (no RCT evidence superior to supportive care, but used in severe cases):

---

5. SEROTONIN SYNDROME

Presentation - Clinical Triad

1. Neuromuscular abnormalities - myoclonus (key distinguishing feature), hyperreflexia, lower extremity rigidity, tremor, ataxia, clonus (ocular, ankle)
2. Autonomic dysfunction - hyperthermia, tachycardia, diaphoresis, mydriasis, diarrhea, hypertension
3. Altered mental status - agitation, confusion, anxiety

• MAOIs + SSRIs (most dangerous combination)
• MAOIs + meperidine, tramadol, dextromethorphan, linezolid, fentanyl
• SSRI + triptans
• SSRI + lithium (high potency), St. John's wort
• Cocaine, amphetamines (moderate potency)

NMS vs. Serotonin Syndrome - Key Differences

Management

1. Discontinue all serotonergic drugs
2. Cardiopulmonary monitoring, IV access, ECG
3. IV fluid rehydration; evaluate for rhabdomyolysis
4. External cooling
5. Benzodiazepines for agitation (lorazepam) - nonspecific serotonin antagonism + muscle relaxation
6. Severe cases: sedation + neuromuscular blockade (non-depolarizing agent) + intubation + ICU admission (~25% require intubation)
7. Short-acting IV antihypertensives (nitroprusside, esmolol) for severe hypertension; direct-acting vasopressors (norepinephrine, phenylephrine) for hypotension (avoid dopamine/epinephrine due to unpredictable response in serotonin-dysregulated state)

• Do NOT give serotonergic agents (meperidine for pain, tramadol, dextromethorphan, triptans)
• Avoid dopamine agonists (bromocriptine) - no benefit, may worsen
• Fluoxetine: prolonged resolution due to long half-life (active metabolite norfluoxetine t½ ~1 week)

---

6. MANIC EPISODE / BIPOLAR EMERGENCY

Presentation

• Elevated or irritable mood, decreased sleep (not tired), grandiosity, pressured speech, flight of ideas, hypersexuality, reckless behavior, psychotic features (in severe mania)
• Emergency: danger to self/others, inability to care for self, mixed state with suicidality

Management

• Calming environment, minimize stimulation
• IM antipsychotic ± lorazepam for severe agitation (same as above)

---

7. ACUTE ALCOHOL WITHDRAWAL / DELIRIUM TREMENS

Presentation timeline

• 6-24 hrs: tremor, anxiety, diaphoresis, tachycardia, hypertension, insomnia
• 12-24 hrs: alcoholic hallucinosis (visual > auditory hallucinations, clear sensorium)
• 24-48 hrs: seizures (grand mal, usually single)
• 48-72 hrs: Delirium Tremens - most severe; confusion, agitation, severe autonomic instability, hyperthermia; mortality 5-15% if untreated

Management - GABA Enhancement (Benzodiazepines are first-line)

• Thiamine 100 mg IV before glucose (prevent Wernicke encephalopathy)
• Magnesium replacement (hypomagnesemia common)
• Multivitamins, folate

• Diazepam in severe liver disease: accumulates (lorazepam preferred)
• Flumazenil is absolutely CONTRAINDICATED in alcohol withdrawal - precipitates seizures by reversing any compensatory GABAergic activity

---

8. OPIOID OVERDOSE (Psychiatric Emergency Overlap)

Presentation

• CNS depression, miosis ("pinpoint pupils"), respiratory depression, apnea, bradycardia, cyanosis

Management

1. Airway, bag-mask ventilation
2. Naloxone (opioid receptor antagonist): 0.4-2 mg IV/IM/IN; repeat every 2-3 minutes; titrate to adequate respirations (not full reversal - precipitates acute withdrawal and agitation)
3. Duration of naloxone (30-90 min) shorter than most opioids - may need repeated dosing or IV infusion (2/3 of initial effective dose per hour)

• No absolute contraindications in life-threatening overdose
• Caution in opioid-dependent patients (acute withdrawal - agitation, vomiting, pulmonary edema, hypertensive crisis); titrate dose to respiratory rate, not consciousness

---

9. STIMULANT (COCAINE / AMPHETAMINE) INTOXICATION

Presentation

• Agitation, paranoia, psychosis, tachycardia, hypertension, hyperthermia, diaphoresis, mydriasis

Management

1. Benzodiazepines first-line (lorazepam 1-2 mg IV/IM, titrate) - treat agitation, hypertension, hyperthermia
2. External cooling for hyperthermia
3. For cocaine-associated chest pain: benzodiazepines reduce demand; avoid beta-blockers - cause unopposed alpha-adrenergic stimulation, worsening coronary vasospasm
4. For hypertension refractory to benzodiazepines: phentolamine (alpha-blocker) or nitrates
5. Antipsychotics (haloperidol) for persistent psychosis not responding to benzodiazepines; lower seizure threshold - use with caution

---

10. ANTICHOLINERGIC TOXIDROME

Presentation - "Hot, Dry, Red, Blind, Mad, Tachy"

• Hyperthermia, dry flushed skin, mydriasis, urinary retention, ileus, tachycardia, delirium/agitation

Management

1. Supportive care, cooling, IV fluids
2. Benzodiazepines for agitation
3. Physostigmine (1-2 mg IV slowly): acetylcholinesterase inhibitor; reverses CNS and peripheral anticholinergic effects; use for refractory severe agitation, seizures, severe hyperthermia

• TCA overdose (risk of severe bradycardia, asystole, seizures) - absolute contraindication
• Reactive airway disease (bronchospasm)
• Bowel/bladder obstruction, ileus
• Cardiac conduction defects

---

11. CATATONIA

Presentation

• Stuporous catatonia: mutism, immobility, waxy flexibility (catalepsy), echopraxia, echolalia, posturing
• Excited catatonia: severe psychomotor agitation, stereotypy
• Malignant catatonia: overlaps with NMS; hyperthermia, autonomic instability

Management

• Lorazepam challenge: 1-2 mg IV - dramatic improvement within minutes strongly supports diagnosis of catatonia (both diagnostic and therapeutic)
• Regular dosing: lorazepam 1-2 mg IV/PO q6-8h; can escalate to 8-24 mg/day for resistant cases

• Most effective treatment for catatonia; indicated when benzodiazepines fail or in malignant catatonia with severe medical compromise
• Acts rapidly; typically 6-12 sessions

• Antipsychotics (especially high-potency FGAs) may worsen catatonia and precipitate NMS
• If psychiatric psychosis co-exists, use low-potency or atypical antipsychotics cautiously after catatonic features respond to benzodiazepines

---

12. ACUTE SUICIDAL OVERDOSE / ANTIDEPRESSANT TOXICITY (TCA)

TCA Overdose - High-Risk Psychiatric Emergency

Management

1. Sodium bicarbonate (1-2 mEq/kg IV bolus): first-line for QRS >100 ms or ventricular arrhythmia; alkalinizes blood (reduces TCA binding to sodium channels) and provides sodium loading; repeat until QRS narrows
2. Lipid emulsion therapy (intralipid) for refractory cardiovascular toxicity
3. Benzodiazepines for seizures (phenytoin is contraindicated - worsens cardiac conduction)
4. Airway management, gastric decontamination if <1 hour and protected airway

• Physostigmine: absolutely contraindicated in TCA overdose (fatal bradycardia/asystole)
• Flumazenil: contraindicated if co-ingestion with benzodiazepines - precipitates seizures
• Phenytoin: worsens TCA cardiac toxicity
• Sodium bicarbonate caution: hypokalemia (worsens QT), volume overload

---

Quick Drug Reference Summary

---

Hospitalization Indications (General)

• Imminent danger to self or others
• Inability to care for self
• First-episode psychosis requiring workup
• Active suicidal ideation with plan/intent or recent attempt
• NMS, serotonin syndrome, DTs (always admit)
• Acute mania with psychosis or reckless behavior
• No adequate outpatient support or follow-up

• Low suicide risk, robust support, means restriction confirmed, follow-up within 24-48 hours
• Mild intoxication resolved with observation, no suicidal ideation
• Chronic presentation with stable baseline and intact outpatient care

---